Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
26 studies found for:    myotonic dystrophy | Interventional Studies
Show Display Options
Rank Status Study
1 Active, not recruiting Clinical Efficacy Trial of Mexiletine for Myotonic Dystrophy Type 1
Condition: Myotonic Dystrophy
Interventions: Drug: Mexiletine;   Drug: Placebo
2 Completed Postural Spirometry Changes in Ambulatory Myotonic Dystrophy Patients
Condition: Myotonic Dystrophy
Intervention: Other: Supine spirometry
3 Completed Efficacy and Safety of DHEA for Myotonic Dystrophy
Condition: Myotonic Dystrophy
Intervention: Drug: dehydroepiandrosterone 100 and 400 mg
4 Recruiting Ventilatory Response After Non Invasive Ventilation in Type 1 Myotonic Dystrophy
Conditions: Myotonic Dystrophy 1;   Steinert Disease
Intervention: Device: Non Invasive Ventilation.
5 Active, not recruiting Observational Prolonged Trial in Myotonic Dystrophy Type 1
Condition: Myotonic Dystrophy Type 1
Intervention: Behavioral: Behavioural change intervention
6 Completed
Has Results
Effects of SomatoKine (Iplex)Recombinant Human Insulin-like Growth Factor-1/Recombinant Human Insulin-like Growth Factor-binding Protein-3 (rhIGF-I/rhIGFBP-3) in Myotonic Dystrophy Type 1 (DM1)
Condition: Myotonic Dystrophy
Intervention: Drug: SomatoKine/IPLEX
7 Recruiting Study of Tideglusib in Adolescent and Adult Patients With Myotonic Dystrophy
Condition: Myotonic Dystrophy 1
Intervention: Drug: Tideglusib
8 Unknown  RAMYD Study - Evaluation of Arrhythmic Risk in Myotonic Dystrophy
Conditions: Myotonic Dystrophy;   Sudden Cardiac Death
Interventions: Procedure: Electrophysiological study;   Device: pacemaker (PM) implant, internal cardiac defibrillator (ICD) implant, loop-recorder implant
9 Completed Methylphenidate in Myotonic Dystrophy Type 1
Condition: Dystrophia Myotonica 1
Interventions: Drug: Methylphenidate;   Drug: Placebo
10 Completed A Safety andTolerability Study of Multiple Doses of ISIS-DMPKRx in Adults With Myotonic Dystrophy Type 1
Condition: Myotonic Dystrophy Type 1
Interventions: Drug: IONIS-DMPKRx;   Drug: Placebo
11 Unknown  Cardiovascular Consequences of NIV Withdrawal in Patients With Myotonic Dystrophy
Condition: Myotonia
Intervention: Other: withdrawal of non-invasive ventilation
12 Unknown  Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1
Condition: Myotonic Dystrophy Type 1
Interventions: Drug: rhIGF-I/rhIGFBP-3;   Drug: placebo
13 Recruiting Efficacy and Tolerance of AVAPS Mode in Myotonic Dystrophy
Condition: Myopathy
Intervention: Device: Nocturnal ventilation
14 Active, not recruiting Efficacy and Tolerance of Early Launching of Nocturnal Non Invasive
Conditions: Myopathy;   Muscular Weakness;   Respiratory Insufficiency
Intervention: Device: Bilevel pressure ventilator
15 Terminated Compare Train and 3D-4D Left Ventricular Systolic Function in Subjects Suffering From Dystrophy and Healthy Subjects
Condition: Steinert's Disease
Interventions: Procedure: electrocardiogram;   Procedure: Echocardiography
16 Terminated Development of New Prenatal Diagnostic Tests From Maternal Blood
Condition: Hereditary Diseases
Intervention: Genetic: Blood samples
17 Recruiting Intramuscular Transplantation of Muscle Derived Stem Cell and Adipose Derived Mesenchymal Stem Cells in Patients With Facioscapulohumeral Dystrophy (FSHD)
Condition: Dystrophy
Intervention: Biological: Intramuscular injection
18 Completed Lamotrigine as Treatment of Myotonia
Conditions: Dystrophia Myotonica Type 1;   Myotonia Congenita;   Paramyotonia Congenita;   Hyperkalemic Periodic Paralysis;   Potassium-Aggravated Myotonia
Interventions: Drug: Lamotrigine;   Drug: Placebo
19 Completed Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP583) for the Treatment of Overactive Bladder Syndrome
Condition: Overactive Bladder Syndrome
Intervention: Drug: SPM 907
20 Completed A Multicenter Trial to Investigate Fesoterodine Sustained Release in Overactive Bladder Syndrome
Condition: Overactive Bladder Syndrome
Intervention: Drug: SPM 907

   Previous Page Studies Shown (1-20) Next Page (21-26) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.